Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of BDP/Salbutamol HFA vs CFC pMDI in Uncontrolled Asthma
NCT00528723Phase 3Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Nov 2007
- Primary completion
- Jan 2009
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial of beclomethasone dipropionate and salbutamol in asthma (2 arms), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoint: Mean value of morning Peak Expiratory Flow. Started Nov 2007; status: completed.
02
Drugs
beclomethasone dipropionatesalbutamol
03
Conditions
asthma
Beyond the preview
Go deeper on NCT00528723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00528723.